BusinessOtonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO® in Pediatric Patients with Acute Otitis Media with Tympanostomy TubesBy Nasdaq OMXOct 4, 2016, 11:30 AM UTC
BusinessOtonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy TubesBy Nasdaq OMXSep 15, 2016, 11:30 AM UTC
BusinessOtonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual MeetingBy Nasdaq OMXSep 13, 2016, 11:30 AM UTC
BusinessOtonomy to Present at Baird Global Healthcare ConferenceBy Nasdaq OMXSep 1, 2016, 11:30 AM UTC
BusinessOtonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing LossBy Nasdaq OMXJan 26, 2016, 12:05 PM UTC
BusinessOtonomy Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesBy Nasdaq OMXJan 12, 2016, 2:27 PM UTC
